Drug & intervention
donanemab
RxCUI 2687966
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
15 shownA Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseNCT06996730 · 2026-07-08
RECRUITINGA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).NCT07602582 · 2026-05-22
RECRUITINGA Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595 · 2026-05-20
RECRUITINGDonanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseNCT07571161 · 2026-04-30
RECRUITINGA Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's DiseaseNCT06566170 · 2024-10-07
RECRUITINGAlzheimer's Tau Platform: Regimen A - AADvac1NCT07167966 · 2026-11-03
ENROLLING_BY_INVITATIONA Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's DiseaseNCT07838155 · 2026-10-01
NOT_YET_RECRUITINGAmyloid Lowering for Alzheimer's in Down's With Donanemab InvestigationNCT06911944 · 2026-08-01
NOT_YET_RECRUITINGA Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486 · 2023-02-28
ACTIVE_NOT_RECRUITINGA Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789 · 2022-10-10
ACTIVE_NOT_RECRUITINGA Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)NCT05108922 · 2021-11-16
COMPLETEDA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866 · 2021-08-27
ACTIVE_NOT_RECRUITINGA Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)NCT04640077 · 2020-11-23
COMPLETEDA Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511 · 2020-06-19
ACTIVE_NOT_RECRUITINGA Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)NCT03367403 · 2017-12-18
COMPLETEDConditions being studied
Alzheimer Disease12Dementia4Brain Diseases3Central Nervous System Diseases3Mental Disorders2Nervous System Diseases2Neurocognitive Disorders2Neurodegenerative Diseases2Alzheimer's Disease1Alzheimers Disease1Amyloid1Amyloid Beta Protein1Autosomal Dominant Alzheimers Disease1Cognitive Dysfunction1Cognitive Impairment1Down Syndrome (DS)1Down Syndrome (Trisomy 21)1Early Onset Alzheimer Disease1Lewy Body Disease1Mild Cognitive Impairment (MCI)1
Research locations
IrvineCalifornia, United States8TampaFlorida, United States8IndianapolisIndiana, United States7JacksonvilleFlorida, United States7OrlandoFlorida, United States7DaytonOhio, United States6HoustonTexas, United States6Las VegasNevada, United States6MiamiFlorida, United States6Winter ParkFlorida, United States6AventuraFlorida, United States5DallasTexas, United States5
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.